EHA 2018 Annual Congress Highlights in Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 5
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, view video highlights from the 2018 European Hematology Association (EHA) Annual Congress and listen as experts share their insights on a variety of abstracts covering topics including, but not limited to: the efficacy and safety of emerging drugs for newly diagnosed and relapsed/refractory AML; monotherapy and combination treatments in clinical trials; and sequencing of therapy for relapsed/refractory disease.
- Chapter 1: Key Findings in AML: An Overview
- Chapter 2: Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 ITD AML
- Chapter 3: Strategies for Achieving Durable Responses in Elderly AML Patients
- Chapter 4: Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML
- Chapter 5: Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Learning ObjectivesUpon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating new and emerging novel therapies and treatment strategies in patients with AML
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in AML
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in AML
Chapter 1: Key Findings in AML: An Overview – Eytan M. Stein, MD
Chapter 2: Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 ITD AML – Mark J. Levis, MD, PhD
- Quizartinib Significantly Prolongs Overall Survival in Patients with FLT3-Internal Tandem Duplication-Mutated (Mut) Relapsed/Refractory AML in the Phase 3, Randomized, Controlled QUANTUM-R Trial (LB2600)
Chapter 3: Strategies for Achieving Durable Responses in Elderly AML Patients – Keith W. Pratz, MD
- Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) (S1563)
Chapter 4: Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML – Eytan M. Stein, MD
- Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (MIDH2) Acute Myeloid Leukemia (AML) (S1561)
- Continuing Enasidenib Treatment for Patients with Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Responses and Survival over Time (PSA980)
Chapter 5: Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML – Jorge E. Cortes, MD
- Outcomes by Number of Induction Cycles with CPX-351 Versus 7+3 Chemotherapy in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (SAML) (PF239)
- A Phase 1 Dose Escalation Study of the IDH1M Inhibitor, FT-2102, in Patients with Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) (PF236)
Instructions for Participation and Credit
This activity is eligible for credit through August 22, 2019. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jorge E. Cortes, MD
Deputy Chair and Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Jorge Cortes received his medical degree from the Universidad Nacional Autonoma de Mexico, Mexico City. He has been at The University of Texas MD Anderson Cancer Center since 1991 where he is currently Deputy Chair and Professor of Medicine in the Department of Leukemia, Section Chief of AML and CML, and the Jane and John Justin Distinguished Chair in Leukemia Research.
Dr. Cortes is also chair of the executive Institutional Review Board (IRB), executive director of the MD Anderson Cancer Center for the Division of Cancer Medicine, and program director of the Leukemia Fellowship Program. He is on the board of directors of the International Chronic Myeloid Leukemia Foundation and president of the Latin American LeukemiaNet. Dr. Cortes has authored more than 900 peer-reviewed medical publications in journals including New England Journal of Medicine, Lancet Oncology, Lancet Hematology, Journal of Clinical Oncology, Leukemia, Blood, and many others. In addition, he has authored several books and book chapters in Cancer Medicine and Harrison’s Principles of Internal Medicine. He is an associate editor for Blood and serves on the editorial board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia & Lymphoma, and the American Journal of Hematology.
Dr. Cortes has received numerous awards and was named among the Highly Cited Researchers in 2014 by Thomson Reuters. He led the development of three drugs that were approved by the US Food and Drug Administration for the treatment of CML in 2012. His clinical interests focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders.
Mark J. Levis, MD, PhD
Professor of Oncology
Director, Adult Leukemia Service
Co-Director, Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dr. Mark Levis completed a baccalaureate in genetics at UC Berkeley, and is a graduate of the Medical Scientist Training Program from UC San Francisco. He completed his residency training in internal medicine and a fellowship in medical oncology at Johns Hopkins University. He is a Professor of Oncology and the Director of the Adult Leukemia Service and Co-Director of the Division of Hematologic Malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. His broad research goals are to identify and validate novel molecular therapeutic targets in hematopoietic malignancies. His research group is interested in the identification and pre-clinical development of novel targeted therapies, and, in particular, the translational step of this research by using correlative studies to incorporate these novel therapies into existing treatments. Currently, Dr. Levis is actively involved in the pre-clinical and clinical development of small molecule kinase inhibitors targeting signaling pathway in acute myeloid leukemia, with a particular focus on FLT3.
Keith W. Pratz, MD
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Dr. Keith Pratz received his medical degree from UMDNJ Robert Wood Johnson Medical School, Camden, New Jersey. He completed his residency in internal medicine at Mayo Graduate School of Medicine, Rochester, Minnesota, and his fellowship in medical oncology at The Johns Hopkins Hospital, Baltimore, Maryland. Dr. Pratz is a clinical investigator of novel therapeutics for acute leukemias and is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is the principal investigator on clinical trials incorporating novel targeted therapies into combination chemotherapy in acute leukemia. Dr. Pratz is also active in designing, coordinating, and conducting laboratory correlative studies in the setting of investigational therapies to aid in the development of improved treatments for hematologic malignancies.
Eytan M. Stein, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-028-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-028-082
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jorge Cortes has received honoraria as a consultant and grant support related to research activities from FORMA Therapeutics, Inc. and Jazz Pharmaceuticals plc.
Dr. Mark Levis has received honoraria as a consultant from Agios, Astellas Pharma US, Inc., Daiichi Sankyo, Inc., Fujifilm Corporation, and Novartis AG. He has received grant support related to research activities from Astellas, Fujifilm, and Novartis.
Dr. Keith Pratz has received honoraria related to formal advisory activities from Astellas Pharma US, Inc. and Boston Scientific Corporation. He has received grant support related to research activities from AbbVie Inc., Agios, Astellas, and Millennium Pharmaceuticals, Inc.
Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Bayer AG, Celgene Corporation, Daiichi Sankyo, Inc., Novartis AG, and Pfizer Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Key Findings in AML: An Overview – Run Time: 11:03
- Chapter 2: Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 ITD AML – Run Time: 9:24
- Chapter 3: Strategies for Achieving Durable Responses in Elderly AML Patients – Run Time: 4:50
- Chapter 4: Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML – Run Time: 7:36
- Chapter 5: Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML – Run Time: 20:26
- Assessment and Evaluation